Electrical Synchronization of Slow Oscillations to Enhance Deep Sleep

NCT ID: NCT04461769

Last Updated: 2020-07-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-01

Study Completion Date

2020-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study applied slowly oscillating (0.5 hz) transcranial electrical stimulation (TES; frontopolar and lateral frontal electrodes versus mastoid and occipital electrode returns) to synchronize the endogenous slow oscillations (SOs) of deep sleep (N3 or stage 3 Non-REM). A double-blind placebo control provided no stimulation. The primary endpoint was duration of N3 sleep during the night. Thirteen normal adults completed the study (before the study was terminated because of COVID-19), and usable data were obtained from ten. The synchronizing stimulation resulted in significantly longer N3 sleep compared to placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Previous studies have demonstrated successful synchronization of SOs with slow TES pulses. However, the stimulation in those studies used electrodes in dorsolateral frontal areas (F3, F4 versus contralateral mastoids), consistent with the assumption that human SOs emanate from frontal neocortex. In the present study, we hypothesized that transcranial electrical stimulation (TES) could be applied to frontopolar and inferior frontal head sites in order to synchronize the limbic sources of SOs specifically and thereby enhance the duration of N3 sleep. Furthermore, based on our computational modeling with this more optimal targeting of the limbic sites, we hypothesized that we could use lower TES current levels (0.5 mA versus 1 or 2 mA in previous studies) that would be unlikely to disrupt sleep and that may still be successful in synchronizing SOs to enhance the adaptive neurophysiology of deep sleep.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Sleep Hygiene

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

First night adaptation sleep; second and third nights (one week apart) stimulation or placebo control (order randomized).
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers
Participants were blind to which night was stimulation. Experimenters were blinded until the participant was asleep, when they opened an email that specified delivery of stimulation or sham.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Slow Oscillation Synchronization with TES

Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.

Group Type EXPERIMENTAL

Transcranial Electrical Stimulation

Intervention Type DEVICE

Oscillating electrical current

Sham Control

No current delivered.

Group Type SHAM_COMPARATOR

Transcranial Electrical Stimulation

Intervention Type DEVICE

Oscillating electrical current

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial Electrical Stimulation

Oscillating electrical current

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sleep WISP (Wireless Interface Sensor Pod)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

* history of seizures
* epilepsy
* brain trauma or injury
* insomnia
* sleep apnea
* medications that may affect the EEG.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brain Electrophysiology Laboratory Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brain Electrophysiology Laboratory Company

Eugene, Oregon, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R44MH115955

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TMS With Real-time E-field and EEG Source Imaging
NCT06645613 NOT_YET_RECRUITING NA
The Effect of Thalamic Stimulation on Sleep Oscillations
NCT07217080 ENROLLING_BY_INVITATION NA
Enhancing Slow Wave Sleep in Depression
NCT07143838 NOT_YET_RECRUITING NA
Multiparameter Optimized tES for Memory in Aging
NCT06491264 NOT_YET_RECRUITING NA
Power Nap With TES-TI
NCT07090135 RECRUITING NA
Sleep TMS for Depression
NCT06824415 COMPLETED NA
At-Home tDCS as Maintenance Therapy
NCT07269964 RECRUITING NA
EEG Synchronized TMS Trial for Depression
NCT03421808 COMPLETED PHASE2/PHASE3